

**PROVIDER NOTIFICATION OF POLICY CRITERIA
CHANGE**

POLICY TITLE	POLICY NUMBER	CRITERIA CHANGE	MATERIAL AMEUREMENT	EFFECTIVE DATE	LINK TO FULL POLICY
Fidanacogene elaparvovec-dzkt (e.g., Beqvez)	2024067	Effective March 6, 2026, this policy will be archived. In February 2026, Pfizer discontinued commercialization and global development of Fidanacogene elaparvovec-dzkt (e.g., Beqvez).	No	05/06/2026	https://secure.arkansasbluecross.com/members/report.aspx?policyNumber=2024067
Self-Administered Medication	2020005	Added Emtricitabine and tenofovir disoproxil fumarate (J0750, J0751) and Lenacapavir (J0752) to the self-administered medication list. Preexposure prophylaxis (PrEP) antiretroviral therapy is covered at no cost-share through the individual's pharmacy benefit.	No	05/06/2026	https://secure.arkansasbluecross.com/members/report.aspx?policyNumber=2020005